Related News
-
4S RANCH: Parents of…
Thursday, August 19, 2010
The parents of a boy suffering from an incurable disease so rare that it only afflicts several dozen American children… more...
-
Cancer Risk Slightly Higher…
Monday, July 19, 2010
Children and young adults who were conceived by in vitro fertilization (IVF) have a slightly increased risk of… more...
-
Elkhart Baby Battling Rare…
Thursday, July 15, 2010
ELKHART — Coen Wing is 6 months old. He weighs 19 pounds, loves his big sister Marissa and gets along great with… more...
-
Positive Clinical Findings…
Thursday, June 17, 2010
ROME -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced… more...
-
Grant to Aid Valley Fever…
Monday, May 31, 2010
A $3 million grant from the National Institutes of Health has been awarded to Tucson-based Valley Fever Solutions Inc.… more...
News
-
CheckOrphan NewsFlash April 30,…
4/30/2010
CheckOrphan NewsFlash for Tuesday, March 30, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
-
CheckOrphan NewsFlash April 9,…
4/09/2010
CheckOrphan NewsFlash for Friday, April 9, 2010: breaking news about rare diseases, orphan diseases, orphan drugs, and…
-
CheckOrphan NewsFlash April 1,…
4/01/2010
CheckOrphan NewsFlash for Thursday, April 1, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
NewsFlash
More News
-
Results From Investigator-Sponsored…
NOVATO, Calif. -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that… more...
-
Celldex Therapeutics Regains Worldwide…
NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today it will… more...
-
Merck Serono's Cladribine Tablets for…
GENEVA, Switzerland -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany,… more...
-
Santhera and Ipsen Enter Into Licensing…
Liestal, Switzerland and Paris, France -- Santhera Pharmaceuticals (SIX: SANN) and Ipsen… more...
-
Celator Pharmaceuticals Raises $20…
Princeton, NJ -- Celator Pharmaceuticals, a privately held pharmaceutical company… more...
Treatment News
EHE International and the Histiocytosis Association of America Want Americans to "Know the Facts" About Histiocytosis
| More
Tuesday, January 5, 2010
PITMAN, NJ -- EHE International and the Histiocytosis Association of America (HAA) are excited to announce the unveiling of a window display at 10 Rockefeller Plaza encouraging Americans to "Know the Facts" about histiocytosis.
Characterized by a build-up of white blood cells known as histiocytes, histiocytosis is a rare and potentially fatal blood disorder. The window will prominently feature images from the HAA's public awareness campaign including faces of patients diagnosed with histiocytosis.
"This opportunity will raise awareness among the public about the plight of histiocytosis and the need for federal research funding," said Executive Director Jeffrey Toughill. "It is important to know that the pain and suffering experienced by people with this disorder can be just as severe as that of people diagnosed with more prevalent diseases, such as leukemia. With the help of the public, physicians, and the family members and friends of patients with histiocytosis, we are able to offer hope for better treatments and a cure for all who suffer from histiocytosis."
The window will be on display for the public from January 4, 2010 until January 29, 2010. "EHE is pleased to offer the Histiocytosis Association of America this window in order to raise awareness for the need of better treatments and a cure of this rare, yet important, disease," said Deb McKeever, EHE President.
In addition to the faces of patients, the window will include important facts about histiocytosis. Approximately 1 in 560,000 adults and 1 in 200,000 children are diagnosed with the disorder in the United States each year. Histiocytosis is classified as an "orphan disease," because it affects too few people to receive government funding for research. Through its annual grant program, the HAA provides financial support to researchers studying the causes and treatment of the disorder.
Founded in 1986, the Histiocytosis Association of America is dedicated to raising awareness about histiocytic disorders, providing educational and emotional support, and funding research leading to better treatments and a cure. You can learn more about the HAA and histiocytosis at the HAA's website, www.histio.org. The site offers a variety of educational and emotional support services and information for patients diagnosed with histiocytosis, their friends and family members, physicians, and members of the public.
EHE International has been the recognized leader in employee and individual Preventive Healthcare Plans (PHP) specifically designed for the early identification of preventable disease and risk factors since 1913; clinical management of health findings; referral resources; and personal coaching intervention programs of adverse lifestyle behaviors associated with poor nutrition, physical inactivity, and smoking. It's nationally available PHP is a comprehensive, integrated approach to preventive healthcare for the reduction and management of future medical claims expense, increased productivity, and overall improved quality of life.
For more information, contact EHE International, 10 Rockefeller Plaza, 4th Floor, New York, New York 10020; 212.332.3702; www.EHEINTL.com.
Contact: Nicolas Danielides Danielides Communications Phone: 212-319-7566 Email: Email Contact
Contact: Jeffrey Toughill Histiocytosis Association of America Phone: 856-589-6606 Email: Email Contact
Source: Histiocytosis Association of America; EHE International
Log in to comment.